University of Vermont Cancer Center
Latest from University of Vermont Cancer Center
Eribulin Elicits Promising 2-Year Overall Survival in Pretreated Metastatic Breast Cancer
March 06, 2022
Article
Real-world findings presented at the 39th Annual Miami Breast Cancer Conference showed that eribulin may be an effective agent for previously treated patients with metastatic breast cancer.